DE60003632D1 - Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten - Google Patents

Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten

Info

Publication number
DE60003632D1
DE60003632D1 DE60003632T DE60003632T DE60003632D1 DE 60003632 D1 DE60003632 D1 DE 60003632D1 DE 60003632 T DE60003632 T DE 60003632T DE 60003632 T DE60003632 T DE 60003632T DE 60003632 D1 DE60003632 D1 DE 60003632D1
Authority
DE
Germany
Prior art keywords
auto
immune diseases
apoptose
treating
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003632T
Other languages
English (en)
Other versions
DE60003632T2 (de
Inventor
Hubertus Noteborn
Maria Pietersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadd BV
Original Assignee
Leadd BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd BV filed Critical Leadd BV
Publication of DE60003632D1 publication Critical patent/DE60003632D1/de
Application granted granted Critical
Publication of DE60003632T2 publication Critical patent/DE60003632T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60003632T 1999-01-11 2000-01-10 Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten Expired - Fee Related DE60003632T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (2)

Publication Number Publication Date
DE60003632D1 true DE60003632D1 (de) 2003-08-07
DE60003632T2 DE60003632T2 (de) 2004-04-15

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003632T Expired - Fee Related DE60003632T2 (de) 1999-01-11 2000-01-10 Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten

Country Status (18)

Country Link
US (1) US20050271624A1 (de)
EP (1) EP1143994B1 (de)
JP (1) JP2003500336A (de)
AT (1) ATE244014T1 (de)
AU (1) AU3083500A (de)
CA (1) CA2359392A1 (de)
DE (1) DE60003632T2 (de)
DK (1) DK1143994T3 (de)
EA (1) EA200100770A1 (de)
ES (1) ES2202039T3 (de)
HU (1) HUP0200552A2 (de)
IL (2) IL144228A0 (de)
MX (1) MXPA01006998A (de)
NO (1) NO20013397L (de)
PT (1) PT1143994E (de)
TR (1) TR200102713T2 (de)
WO (1) WO2000041497A2 (de)
ZA (1) ZA200105632B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079222A2 (en) * 2001-03-30 2002-10-10 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
US6924266B2 (en) * 2001-05-25 2005-08-02 Nymox Corporation NTP-peptides and method for removal of tumors
PL207588B1 (pl) * 2001-07-19 2011-01-31 Nymox Corp Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
JP2001516210A (ja) * 1997-02-28 2001-09-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症細胞の自己調節されたアポトーシス
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody

Also Published As

Publication number Publication date
WO2000041497A2 (en) 2000-07-20
JP2003500336A (ja) 2003-01-07
HUP0200552A2 (en) 2002-06-29
EA200100770A1 (ru) 2002-02-28
PT1143994E (pt) 2003-11-28
NO20013397L (no) 2001-09-11
ZA200105632B (en) 2002-10-09
TR200102713T2 (tr) 2002-05-21
ATE244014T1 (de) 2003-07-15
IL144228A0 (en) 2002-05-23
EP1143994B1 (de) 2003-07-02
ES2202039T3 (es) 2004-04-01
EP1143994A2 (de) 2001-10-17
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01
DE60003632T2 (de) 2004-04-15
IL144228A (en) 2009-06-15
NO20013397D0 (no) 2001-07-09
CA2359392A1 (en) 2000-07-20
US20050271624A1 (en) 2005-12-08
DK1143994T3 (da) 2003-10-20
WO2000041497A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
TNSN08064A1 (en) Albumin fusion proteins
EA200800094A1 (ru) Антитела cd19 и их использование
NO20064059L (no) Albumin fusjonsproteiner
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2001045746A3 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
ATE403680T1 (de) Herstellung tetravalenter antikörper
SG170080A1 (en) Human monoclonal antibodies to o8e
DE60224291D1 (de) System zur antikörperexpression und- synthese
HUP0103758A2 (hu) Neurotróf faktorok
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
ATE431405T1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
DE60003632D1 (de) Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
ATE479705T1 (de) Reduzierter slam abhängiger zell eintritt
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
WO2002072632A3 (en) Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
Gilbert et al. Purification of fibrinogen and virus removal using preparative electrophoresis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee